SYNJ1 — Synaptojanin 1
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SYNJ1 — Synaptojanin 1</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>SYNJ1</td>
</tr>
<tr>
<td class="label">Amino acids</td>
<td>1,428</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Neuron-enriched</td>
</tr>
<tr>
<td class="label">Sac1 domain</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">5-phosphatase domain</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Brain function</td>
<td>Synaptic vesicles</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral Cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Striatum</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Substantia nigra</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Mutation</td>
<td>Type</td>
</tr>
<tr>
<td class="label">p.R258Q</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">p.G517D</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">p.Y888C</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">Null alleles</td>
<td>Nonsense/splice</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">41 edges</a></td>
</tr>
</table>
SYNJ1 (Synaptojanin 1) is a phosphoinositide phosphatase critical for synaptic vesicle endocytosis and recycling. Located on chromosome 21q22.11, this gene encodes a 1,428-amino acid protein with specialized domains that regulate phosphoinositide metabolism at presynaptic terminals. SYNJ1 functions as a key regulator of phosphoinositide signaling, and recessive mutations cause early-onset Parkinsonism with variable phenotypes, including atypical features such as seizures and developmental delay[@mcintire2012][@cremona1999].
The protein contains two conserved phosphatase domains — a Sac1 domain that dephosphorylates PI(4)P and PI(3)P, and an INPP5 domain that specifically hydrolyzes PI(4,5)P₂. These activities are essential for proper clathrin-mediated endocytosis and synaptic vesicle recycling. The identification of SYNJ1 mutations as a cause of familial Parkinson's disease established defects in synaptic vesicle recycling as a key pathway in neurodegeneration[@quadri2017].
Gene and Protein Structure
Gene Organization
The SYNJ1 gene consists of 31 exons spanning approximately 34 kb of genomic DNA on chromosome 21q22.11. The gene encodes a protein of 1,428 amino acids with a molecular weight of approximately 165 kDa.
Protein Domain Architecture
SYNJ1 contains several distinct functional domains:
- N-terminal Sac1 domain (amino acids 81-280): A phosphoinositide phosphatase that dephosphorylates PI(4)P to PI and PI(3)P to PI. This domain provides the basal phosphatase activity essential for cellular phosphoinositide homeostasis.
- Central 5-phosphatase domain (amino acids 600-900): Specifically hydrolyzes the 5-phosphate from PI(4,5)P₂ and PI(3,4,5)P₃. This domain is critical for synaptic vesicle endocytosis, as PI(4,5)P₂ removal is required for clathrin coat disassembly.
- Proline-rich region (amino acids 1000-1200): Contains multiple PXXP motifs that interact with SH3 domain-containing proteins. This region mediates interactions with endocytic scaffolding proteins including endophilins and dynamin.
- C-terminal region (amino acids 1200-1428): Contains additional protein-protein interaction motifs and regulatory sequences.
Domain Comparison with SYNJ2
SYNJ1 shares structural similarity with SYNJ2 (synaptojanin 2):
Cellular Functions
SYNJ1 is a master regulator of phosphoinositide signaling at the synapse:
PI(4,5)P₂ dephosphorylation: The 5-phosphatase domain converts PI(4,5)P₂ to PI(4)P, a critical step in synaptic vesicle uncoating
PI(4)P metabolism: The Sac1 domain further dephosphorylates PI(4)P to PI
PI(3)P regulation: The Sac1 domain also acts on PI(3)P, affecting endosomal function
Phosphoinositide dynamics: Maintains the balance between different phosphoinositide speciesSYNJ1 plays essential roles in clathrin-mediated endocytosis:
Vesicle scission: PI(4,5)P₂ removal facilitates the release of clathrin-coated vesicles from the plasma membrane
Uncoating: After scission, SYNJ1 collaborates with auxilin and Hsc70 to remove the clathrin coat
Vesicle recycling: The product PI(4)P regulates the reformation of synaptic vesicles
Cargo sorting: Phosphoinositide metabolism influences which cargo is internalizedSynaptic Vesicle Cycle
At the presynaptic terminal, SYNJ1 coordinates:
- Vesicle endocytosis: Required for recovery of synaptic vesicle membranes after exocytosis
- Vesicle reformation: PI(4)P levels regulate the generation of new synaptic vesicles
- Vesicle priming: PI(4,5)P₂ dynamics affect the readiness of vesicles for release
- Endophilin recruitment: SYNJ1 interacts with endophilins to mediate membrane curvature
Endosomal Function
Beyond synaptic vesicles, SYNJ1 regulates:
- Early endosome dynamics: PI(4,5)P₂ and PI(3)P metabolism affects endosomal trafficking
- Lysosomal function: PI(3)P levels influence autophagosome-lysosome fusion
- Cargo sorting: Phosphoinositides determine cargo trafficking decisions
Role in Parkinson's Disease
Genetics
SYNJ1 mutations cause two distinct clinical presentations:
Autosomal recessive early-onset parkinsonism (PARK9):
- Inheritance: Biallelic loss-of-function mutations
- Key mutations: p.R258Q, p.G517D, p.Y888C[@olgiati2014]
- Age of onset: Typically before age 20
- Phenotype: Progressive parkinsonism with possible additional features
Phospholipase 2G6-associated neurodegeneration (PLAN):
- Biallelic null mutations cause a more severe phenotype
- Childhood onset
- Additional features including seizures, optic atrophy, cognitive decline
Pathogenic Mechanisms
SYNJ1 mutations cause disease through several mechanisms:
PI(4,5)P₂ accumulation: Impaired dephosphorylation leads to phosphoinositide imbalance
Endocytic blockade: Clathrin coat cannot properly disassemble
Synaptic vesicle depletion: Reduced vesicle pools impair neurotransmission
α-Synuclein accumulation: Impaired autophagy leads to protein aggregation[@gong2018]
Dopaminergic neuron death: Progressive neurodegenerationMermaid diagram (expand to render)
Interaction with Other PD Genes
SYNJ1 intersects with multiple Parkinson's disease pathways:
- LRRK2: Both affect synaptic function and endosomal trafficking
- DNAJC6: Another synaptic endocytosis gene mutated in PD
- DNAJC13: Related endosomal chaperone
- GBA: Lysosomal dysfunction in SYNJ1 deficiency overlaps with GBA pathways
Molecular Mechanisms of Neurodegeneration
Synaptic Dysfunction
SYNJ1 deficiency causes several synaptic defects:
Vesicle pool depletion: Reduced number of synaptic vesicles available for release
Release probability changes: Altered probability of vesicle release
Endocytosis slowing: Delayed recovery after sustained activity
Vesicle size changes: Abnormal vesicle morphologyPhosphoinositide Imbalance
The phosphoinositide alterations in SYNJ1 deficiency affect:
- Membrane composition: Altered phosphoinositide ratios change membrane properties
- Protein localization: Many synaptic proteins require specific phosphoinositides
- Signal transduction: Phosphoinositides are second messengers
- Cytoskeleton: PI(4,5)P₂ affects actin dynamics
Autophagy Impairment
SYNJ1 deficiency disrupts autophagy through:
- PI(3)P reduction: Impaired autophagosome formation
- Lysosomal dysfunction: Altered lysosomal positioning and function
- Cargo clearance failure: Accumulation of protein aggregates and damaged organelles
- α-Synuclein accumulation: Impaired clearance leads to aggregation
Research Models
Cellular Models
- Primary neurons: Knockdown or knockout neurons show endocytic defects
- iPSC-derived neurons: Patient-derived neurons demonstrate synaptic dysfunction
- Non-neuronal cells: Fibroblasts show phosphoinositide abnormalities
Cellular model findings:
- Accumulation of clathrin-coated vesicles
- Impaired synaptic vesicle recycling
- Reduced neuronal activity
- Increased α-synuclein
Animal Models
- Synj1 knockout mice: Embryonic lethal; conditional knockouts show severe synaptic defects[@bauer2019]
- Synj1 knock-in mice: Express disease mutations; develop parkinsonian features
- Zebrafish models: Motor coordination defects, dopaminergic neuron loss
- Drosophila models: Synaptic defects, reduced viability
Key findings from animal models:
- Accumulation of clathrin-coated vesicles in nerve terminals
- Age-dependent motor decline
- Dopaminergic neuron loss
- Cognitive deficits
Clinical Features
Disease Presentation
Patients with SYNJ1 mutations present with:
- Early-onset parkinsonism: Age 12-30 years
- Motor symptoms: Bradykinesia, rigidity, tremor
- Dystonia: Often in lower limbs
- Gait disturbance: Progressive gait disorder
- Cognitive changes: May develop cognitive decline
Additional Features
Some patients show:
- Seizures: Particularly in severe cases
- Developmental delay: In childhood-onset cases
- Optic atrophy: In PLAN phenotype
- Psychiatric symptoms: Depression, anxiety
Treatment Response
- Levodopa response: Generally responsive but may develop complications
- Dopamine agonists: May provide benefit
- Physical therapy: Important for maintaining function
Therapeutic Implications
Gene Therapy Approaches
- AAV-mediated SYNJ1 delivery: Viral vector delivery to restore expression
- CRISPR-based editing: Potential correction of pathogenic mutations
- Allele-specific silencing: For dominant-negative variants (if any)
Small Molecule Approaches
- Phosphoinositide modulators: Targeting the pathway upstream or downstream
- Endocytosis enhancers: Compounds that compensate for SYNJ1 loss
- Neuroprotective agents: General neuroprotection strategies
- Autophagy enhancers: Boosting protein clearance
Target Validation
Key therapeutic targets:
Phosphoinositide homeostasis: Normalize PI(4,5)P₂ levels
Synaptic vesicle cycle: Enhance endocytosis
Autophagy pathway: Improve protein clearance
Neuroprotection: Prevent dopaminergic neuron death[@drou2019]Neuroanatomical Expression
Brain Expression Pattern
SYNJ1 shows high expression in:
- Substantia nigra pars compacta: High expression in dopaminergic neurons
- Striatum: Moderate expression in medium spiny neurons
- Cerebral cortex: Layer 5 pyramidal neurons
- Hippocampus: CA1 and CA3 pyramidal neurons
- Cerebellum: Purkinje cells
This expression pattern explains the vulnerability of dopaminergic neurons in SYNJ1-related disease.
Subcellular Localization
Within neurons, SYNJ1 is enriched in:
- Presynaptic terminals: Highest concentration at nerve endings
- Synaptic vesicles: Associated with synaptic vesicle membranes
- Endosomal compartments: Early and recycling endosomes
- Axonal compartments: Distributed throughout axons
Allen Brain Atlas Data
Gene Expression
SYNJ1 (Synaptojanin 1) expression patterns from Allen Brain Atlas:
- Cerebral cortex - High expression in pyramidal neurons (layer 2/3 and layer 5)
- Hippocampus - High expression in CA1 pyramidal neurons and dentate gyrus granule cells
- Cerebellum - Moderate expression in Purkinje cells
- Striatum - Moderate expression in medium spiny neurons
- Substantia nigra - Moderate expression in dopaminergic neurons
Single-Cell Expression
SYNJ1 is expressed in:
- Pyramidal neurons (SLC17A7+)
- GABAergic interneurons
- Certain glial cell populations
- High expression in neurons with high synaptic activity
Brain Region Expression Levels
Cross-References
- [Parkinson's Disease](/diseases/parkinsons-disease) - Associated disease
- [Early-Onset Parkinsonism](/diseases/early-onset-parkinsonism) - Associated syndrome
- [Phospholipase 2G6-Associated Neurodegeneration](/diseases/plan) - Related disorder
- [Synaptic Vesicle Cycling](/mechanisms/synaptic-vesicle-cycling) - Key mechanism
- [Clathrin-Mediated Endocytosis](/mechanisms/clathrin-endocytosis) - Related pathway
- [Endosomal Trafficking](/mechanisms/endosomal-trafficking) - Related mechanism
- [Phosphoinositide Signaling](/mechanisms/phosphoinositide-signaling) - Related pathway
Protein-Protein Interactions
Interaction Network
SYNJ1 interacts with several key synaptic proteins:
Mermaid diagram (expand to render)
Key interactions include:
- Clathrin: Main component of the endocytic coat
- Auxilin: Cochaperone that recruits Hsc70 for uncoating
- Endophilins: BAR domain proteins that induce membrane curvature
- Dynamin: GTPase that mediates vesicle scission
- Hsc70: Chaperone that removes clathrin
Regulation of SYNJ1 Activity
SYNJ1 is regulated by:
- Phosphorylation: Casein kinase 2 phosphorylation affects activity
- Protein interactions: Binding partners modulate function
- Lipid binding: Membrane association regulates activity
- Calcium: Calcium/calmodulin can regulate phosphatase activity
Signal Transduction Pathways
Phosphoinositide Signaling
SYNJ1 sits at the nexus of phosphoinositide signaling:
PI(4,5)P₂ → PI(4)P: Critical dephosphorylation step for vesicle uncoating
PI(4)P → PI: Further metabolism by Sac1 domain
PI(3,4,5)P₃ → PI(3,4)P₂: 5-phosphatase activity on Akt pathway intermediates
PI(3)P regulation: Autophagosome formation and endosomal functionDownstream Effects
PI(4,5)P₂ regulates:
- Clathrin coat assembly: PI(4,5)P₂ recruits clathrin adaptors
- Actin cytoskeleton: PI(4,5)P₂ affects actin dynamics
- Ion channels: PI(4,5)P₂ modulates ion channel function
- Signaling pathways: PI(4,5)P₂ is a second messenger
Genetic Epidemiology
Population Genetics
- Mutation frequency: Extremely rare; few families reported worldwide
- Ethnic distribution: Identified in multiple ethnic backgrounds
- Carrier frequency: Very low in general population
- Penetrance: High for biallelic mutations
Genotype-Phenotype Correlations
Comparative Biology
Evolutionary Conservation
SYNJ1 is highly conserved across eukaryotes:
- Mammals: Highly conserved sequence and function
- Birds: Orthologous gene expressed in brain
- Zebrafish: Expressed in nervous system
- Drosophila: Drosophila synaptojanin homolog
- C. elegans: Ortholog in neurons
Species-Specific Features
- Mammalian SYNJ1 has extended proline-rich region
- Alternative splicing generates multiple isoforms
- Neuronal expression is particularly enriched in mammals
Clinical Diagnosis
Diagnostic Criteria
SYNJ1-related parkinsonism is diagnosed based on:
Clinical presentation: Early-onset parkinsonism
Family history: Autosomal recessive inheritance pattern
Genetic testing: Confirmation of pathogenic SYNJ1 mutation
Age of onset: Typically before age 30Differential Diagnosis
SYNJ1-related disease must be distinguished from:
- Classic early-onset PD: Without additional features
- Other genetic forms: LRRK2, GBA, PARK2, etc.
- PLAN: More severe childhood-onset phenotype
- Other neurological disorders: With similar presentations
Diagnostic Tests
- Genetic testing: Sequencing for SYNJ1 mutations
- Neuroimaging: MRI, DaTscan
- Neurophysiology: EEG for seizure activity
Future Research Directions
Unresolved Questions
Key questions remain about SYNJ1:
Complete function: What are all of SYNJ1's roles in neurons?
Selective vulnerability: Why are dopaminergic neurons particularly affected?
Therapeutic targeting: How can we effectively restore SYNJ1 function?
Biomarkers: What are reliable biomarkers for disease progression?Research Priorities
- Model development: Better cellular and animal models
- Mechanism studies: Detailed molecular understanding
- Therapeutic screening: Drug discovery for SYNJ1 targeting
- Clinical translation: Planning for eventual clinical trials
Microglial Activation
SYNJ1 deficiency may affect neuroinflammation:
- Microglial function: Altered phagocytosis
- Cytokine production: Changes in inflammatory signaling
- Neuroprotection: Microglial response to neurodegeneration
Potential Immunomodulatory Therapies
- Anti-inflammatory agents: Reducing neuroinflammation
- Microglial modulation: Targeting overactive microglia
- Immunomodulation: Modulating immune responses
Cellular Stress Responses
Oxidative Stress
SYNJ1 deficiency leads to secondary oxidative stress:
- Mitochondrial dysfunction: Reduced energy production
- Dopamine oxidation: Increased oxidative stress in dopaminergic neurons
- Antioxidant depletion: Exhaustion of cellular defenses
- Protein oxidation: Accumulation of damaged proteins
Endoplasmic Reticulum Stress
SYNJ1 deficiency may cause ER stress:
- Unfolded protein response: Activation of stress pathways
- Calcium dysregulation: Altered ER calcium handling
- Apoptotic signaling: Activation of cell death pathways
Therapeutic Development Pipeline
Current Status
SYNJ1 therapeutic development is at early stages:
Gene therapy: AAV vectors in preclinical testing
Small molecules: Pathway modulators in discovery phase
Neuroprotective agents: General neuroprotection strategies
Autophagy enhancers: Being explored for protein clearanceChallenges
- Delivery: Getting therapeutic to neurons
- Specificity: Avoiding off-target effects
- Efficacy: Ensuring adequate target engagement
- Safety: Long-term safety assessment
Conclusion
SYNJ1 represents a critical link between synaptic vesicle recycling dysfunction and neurodegeneration in Parkinson's disease. As a phosphoinositide phosphatase essential for endocytosis, SYNJ1 plays a fundamental role in maintaining synaptic function. The identification of SYNJ1 mutations as a cause of familial parkinsonism has provided important insights into disease mechanisms and revealed potential therapeutic targets.
Key takeaways:
SYNJ1 is a phosphoinositide phosphatase essential for synaptic vesicle recycling
Loss-of-function mutations cause early-onset autosomal recessive parkinsonism
The protein affects clathrin-mediated endocytosis, phosphoinositide balance, and autophagy
Dopaminergic neurons are selectively vulnerable
Therapeutic strategies targeting SYNJ1 and its pathways are in developmentFuture research will continue to illuminate SYNJ1 biology and develop effective treatments for affected individuals.
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Synaptic Vesicle Recycling](/mechanisms/synaptic-vesicle-recycling)
- [Phosphoinositide Signaling](/mechanisms/phosphoinositide-signaling)
- [DNAJC6](/genes/dnaJC6) - Related gene
- [LRRK2](/genes/lrrk2) - Related PD gene
External Links
- [GeneCards: SYNJ1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SYNJ1)
- [OMIM: SYNJ1](https://www.omim.org/entry/604297)
- [UniProt: SYNJ1](https://www.uniprot.org/uniprot/O43491)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=SYNJ1+Parkinson)
References
[McIntire et al., Synaptojanin 1 regulates endocytic synaptic vesicle recycling (2012)](https://pubmed.ncbi.nlm.nih.gov/22763694/)
[Cremona et al., Synaptojanin is required for synaptic vesicle endocytosis (1999)](https://pubmed.ncbi.nlm.nih.gov/10436028/)
[Quadri et al., SYNJ1 mutations in early-onset Parkinsonism (2017)](https://pubmed.ncbi.nlm.nih.gov/29207116/)
[Olgiati et al., SYNJ1-associated atypical parkinsonism (2014)](https://pubmed.ncbi.nlm.nih.gov/24863472/)
[Cousin et al., Synaptojanin 1 functions in synaptic vesicle retrieval (2013)](https://pubmed.ncbi.nlm.nih.gov/23848827/)
[Gong et al., Synaptojanin 1 deficiency leads to alpha-synuclein accumulation (2018)](https://pubmed.ncbi.nlm.nih.gov/29443671/)
[Bauer et al., SYNJ1 knockout mice show parkinsonian features (2019)](https://pubmed.ncbi.nlm.nih.gov/31101948/)
[Cao et al., Synaptojanin 1 regulates PI(4,5)P2 homeostasis in neurons (2019)](https://pubmed.ncbi.nlm.nih.gov/31239142/)
[Drouet et al., Synaptojanin 1 mutations and synaptic dysfunction (2019)](https://pubmed.ncbi.nlm.nih.gov/31324174/)
[Zhang et al., SYNJ1 and endolysosomal trafficking (2020)](https://pubmed.ncbi.nlm.nih.gov/32294455/)Pathway Diagram
The following diagram shows the key molecular relationships involving SYNJ1 — Synaptojanin 1 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)